IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility

IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting

IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer